my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
13-06-2012: Multiplicom, a molecular diagnostics company specializing in the design, development, production and commercialization of molecular genetic tests based on massively parallel sequencing, announced that it has been awarded a €200,000 grant from the Flemish agency for Innovation by Science and Technology (IWT). The grant is intended to support the development of a test for genetic abnormalities during pregnancy that needs only a blood sample, in contrast to the invasive screening methods in use today. The test will be based on Multiplicom’s proprietary MASTR (Multiplex Amplification of Specific Targets for Resequencing) workflow.
The test, a single tube multiplex PCR reaction starting from fetal DNA isolated from the mother’s blood, allows the identification of copy number variations (or ‘aneuploidies’) of chromosomes 21, 18, 13, X and Y. Such variations cause genetic diseases like Down’s syndrome, Edward’s syndrome, Patau syndrome, triple X syndrome and Klinefelter’s syndrome.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Biocartis strengthens management team with general counsel
Biocartis announced that Inge Basteleurs has joined the company as General Counsel. Inge will be a member of Biocartis’ Executive Committee and a director of Biocartis NV. Inge Basteleurs brings to Biocartis a 17-year career as a senior international executive within the biotechnology and p ... more
Multiplicom receives €200,000 grant for novel non-invasive pre-natal test
Multiplicom, a molecular diagnostics company specializing in the design, development, production and commercialization of molecular genetic tests based on massively parallel sequencing, announced that it has been awarded a €200,000 grant from the Flemish agency for Innovation by Science and ... more
Karyopharm Therapeutics Inc. has initiated an exclusive collaboration in the area of Selective Inhibitors of Nuclear Export (SINE) modulators of the CRM1 protein with the Rega Institute for Medical Research, a part of the Katholieke University of Leuven (K.U.Leuven), Belgium. The nuclear tr ... more
FlandersBio is the umbrella organisation for the Life Sciences sector in Flanders, a dynamic non-profit, fee based organisation with 210 members. Its mission is to support and facilitate the sector’s sustained development. more
Multiplicom receives €200,000 grant for novel non-invasive pre-natal test
Multiplicom, a molecular diagnostics company specializing in the design, development, production and commercialization of molecular genetic tests based on massively parallel sequencing, announced that it has been awarded a €200,000 grant from the Flemish agency for Innovation by Science and ... more
Athersys Awarded $3.6 Million in Grant Funding For Stem Cell Product Development
Athersys, Inc. announced grant funding aggregating $3.6 million to further advance its MultiStem® product programs and cell therapy platform. Specifically, Athersys was awarded a SBIR Fast-Track grant of up to $1.9 million from the National Institute of Neurological Disorders and Stroke ( ... more
IWT helps to accelerate reMYND’s Diabetes program with a grant of 1.48 million EUR for 2011-2012
reMYND NV announced that it has received a grant of 1.48 million EUR from IWT, the Flemish agency for Innovation by Science and Technology, to accelerate its Diabetes program. reMYND’s Drug Discovery & Development focuses on the development of disease-modifying drugs for patients suffering ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
